Do TZDs increase the risk of heart failure for patients with diabetes?

Journal of Family Practice

Volumn 54, Issue 8, 2005, Pages 723-724

  Baskin, Serena ^a   Neher, Jon O ^a   Dodson, Sherry ^b  

^a Valley Family Medicine Residency   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; ANTIDIABETIC AGENT;

CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG CONTRAINDICATION; HEART FAILURE; HUMAN; PATIENT MONITORING; REVIEW; CHEMICALLY INDUCED DISORDER; RISK;

DIABETES MELLITUS; HEART FAILURE, CONGESTIVE; HUMANS; HYPOGLYCEMIC AGENTS; RISK; THIAZOLIDINEDIONES;

EID: 23444460213     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (4)

1. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003; 26:2983-2989.
2. Belcher G, Lambert C, Goh KL, Edwards G, Valbuena M. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract 2004; 58:833-837.
3. Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther 2004; 26:1400-1410.
4. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association, October 7, 2003. Circulation 2003; 108:2941-2948.